Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

Sorry, there's nothing here.
0100200300'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

1,826 Citations

Semantic Scholar estimates that this publication has 1,826 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Willett2005SurrogateMF, title={Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.}, author={Christopher G Willett and Yves Boucher and Dan G Duda and Emmanuelle di Tomaso and Lance L. Munn and Ricky Tong and Sergey V. Kozin and Lucine Petit and Rakesh K. Jain and Daniel C. Chung and Dushyant V. Sahani and Sanjeeva Prasad Kalva and Kenneth S. Cohen and David T Scadden and Alan J. Fischman and J. W. Clark and David P. Ryan and Andrew X. Zhu and Lawrence Scott Blaszkowsky and Paul C. Shellito and Mari Mino-Kenudson and Gregory Yves Lauwers}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2005}, volume={23 31}, pages={8136-9} }